ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES THE ASPIRATIONAL AND PRACTICAL ELEMENTS OF GENERATING REAL-WORLD EVIDENCE

Published Nov 2, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) hosted an issue panel this afternoon entitled, Real World Evidence to Support Value Proposition and Reimbursement at Launch: The Aspirational Meets the Impractical?, at the Society’s 19th Annual European Congress in Vienna, Austria. The issue panel was moderated by Kari Edwards, PhD, Managing Partner, Harbinger Health, LLC, Los Angeles, CA, USA. Panelists for the session included:
  • Adrian R. Levy, PhD, Professor and Head, Community Health and Epidemiology, Dalhousie University, Nova Scotia, AL, Canada
  • Arie Barlev, PharmD, MS, Senior Director, Health Economics and Outcomes Research, Medivation, Inc., San Francisco, CA, USA
  • Andrew Briggs, DPhil, William R. Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK
The panelists explored the tension that exists between the aspirational and practical elements of generating real-world evidence in a timely fashion to support reimbursement for the launch of a new product launch. Kari Edwards, PhD presented a number of illustrative case studies to provide context and moderated the debate. Adrian R. Levy, PhD provided a payer perspective, arguing in favor of real-world evidence and noting that timely assessment of likely effectiveness would support reimbursement submissions upon product launch. Arie Barlev, PharmD, MS presented an industry view noting the practical challenges associated with collecting evidence within a short, post-approval timeframe, and highlighted the problem of selection bias when measuring relative effect in populations exposed to newly approved agents compared with standards of care. The final speaker, Andrew Briggs, DPhil, represented the health economics point of view and demonstrated the use of modeling techniques to exploit the rigorous nature of clinical trial data. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×